Yarrow Bioscience (YARW) EBITDA (2017 - 2026)

Yarrow Bioscience (YARW) has reported EBITDA for 10 consecutive years, with -$3.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA rose 58.87% year-over-year to -$3.1 million; the trailing twelve-month figure through Jun 2026 stood at -$23.7 million (up 44.47% YoY), and the FY2025 full-year result was -$29.7 million, up 31.83% from the prior year.
• EBITDA improved to -$3.1 million in Q2 2026 per YARW's latest filing, from -$3.8 million in the prior quarter.
• Across five years, EBITDA topped out at -$3.1 million in Q2 2026 and bottomed at -$13.1 million in Q3 2024.
• Historically, EBITDA has averaged -$8.2 million across 5 years, with a median of -$8.1 million in 2022.
• The sharpest annual moves came in 2024 and 2026: EBITDA plunged 109.99% in 2024, then jumped 58.87% in 2026.
• Over 5 years, EBITDA stood at -$8.0 million in 2022, then grew by 14.43% to -$6.8 million in 2023, then sank by 86.91% to -$12.8 million in 2024, then soared by 40.94% to -$7.5 million in 2025, then surged by 58.87% to -$3.1 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$3.1 million, -$3.8 million, and -$7.5 million for Q2 2026, Q1 2026, and Q2 2025 respectively.